Navigation Links
Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
Date:8/17/2011

LIBERTY, Mo. and DANBURY, Conn., Aug. 17, 2011 /PRNewswire/ -- Planet Biopharmaceuticals, Inc. and its wholly owned Subsidiaries (collectively, "Planet"), a privately held specialty pharmaceutical company focused on providing products for allergy and asthma sufferers, today announced that Theron (Ted) E. Odlaug, Ph.D. has been named as the company's Executive Chairman and will assume the additional role of Chief Executive Officer on August 29, 2011. Odlaug will replace William (Bill) Goldberg, who has joined MediMedia USA, Inc. as Chief Executive Officer. Goldberg will remain on Planet's board of directors as an independent director.

Odlaug will be responsible for day-to-day operations and corporate strategy. "Ted's extensive experience in the pharmaceutical and life sciences arenas make him the ideal candidate to lead the company," said Goldberg.

Scott Glenn, Chairman, commented, "Ted has an impressive record of accomplishment. We are confident in his ability to guide Planet through its next stage of corporate development. We also thank Bill for the tremendous job he has done with Planet. We wish him well in his new role with MediMedia."

"I am pleased to lead Planet at such an exciting time in the company's history," said Odlaug.

From 2008 until January of this year Ted was President and CEO of CyDex Pharmaceuticals, Inc when the company was sold under Ted's leadership to Ligand Pharmaceuticals, Inc. Prior to CyDex, Ted served as Managing Partner of EIR Healthcare Advisors, LLC. Prior to that, he was Executive Vice President and a member of the senior management committee at Fujisawa Healthcare Inc. until its merger with Yamanouchi in 2005, which resulted in the formation of Astellas Pharma. He left Astellas in 2006 after successfully supporting the U.S. post-merger integration process.

Odlaug holds Bachelor's and Master's degrees from the University of Missouri at Kansas City and a Ph.D. in Public Health from the University of Minnesota.

Contact:

Planet Biopharmaceuticals, Inc.
Francesca DiNota, Vice President and CFO
816-792-8512


'/>"/>
SOURCE Planet Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Technology to Revolutionize the Way the Planet Does Business
2. Fountain Healthy Aging Inc Announces Agreement to Acquire Natural Planet USA
3. DNA-Planet Launches New Service for Customer-Individual Indirect DNA Paternity Testing and Kinship Analysis
4. The Biotechnology Industry Organization and Critical Path Institute Partner With Mediaplanet, Biocom, and the University of California Office to Spotlight the Science That Is Healing, Fueling and Feeding Our Global Population
5. Mediaplanet Launches Campaign for Awareness of Neurological Issues
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... -- AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), a ... a majority-owned subsidiary of Intrexon Corporation (NYSE: ... of its common shares on the NASDAQ Stock Market ... "AquaBounty,s listing on NASDAQ represents an important milestone for ... U.S. markets as we advance plans for commercial production ...
(Date:1/19/2017)... Linda, Ca (PRWEB) , ... January 18, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, was ... American News. The awards program is based entirely on merit and decided upon ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
Breaking Biology Technology:
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)... 12, 2017 A new report by Allied Market Research, titled, ... biometric technology market is expected to generate revenue of $10.72 billion by 2022, with ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
Breaking Biology News(10 mins):